Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
By Colin Kellaher
Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for adolescents with a sinus condition that can lead to a loss of the sense of smell.
Regeneron and Sanofi on Monday said the application covers Dupixent as an add-on maintenance treatment for patients ages 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis, or CRSwNP.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The agency has set a target action date of Sept. 15 for the application.
Regeneron and Sanofi said an FDA green light would make Dupixent the first treatment in the U.S. for those ages 12 to 17 with inadequately controlled CRSwNP, which is driven in part by an underlying type 2 inflammation that obstructs the sinuses and nasal passages. Dupixent is currently approved as an add-on maintenance treatment for adults with CRSwNP whose disease isn't adequately controlled.
Tarrytown, N.Y., biotechnology company Regeneron created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement, while Sanofi markets the product internationally. The drug generated roughly $11.6 billion in sales last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2024 06:24 ET (10:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations